# DAFTAR PUSTAKA


Abu el Maaty, M. A., Terzic, J., Keime, C., Rovito, D., Lutzing, R., Yanushko, D., Parisotto, M., Grelet, E., Namer, I. J., Lindner, V., Laverny, G., & Metzger, D. (2022). Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression. *Science Advances*, *8*(29), 1–15. https://doi.org/10.1126/sciadv.abo2295

Amin, M. B., & Tickoo, S. K. (2016). Diagnostic Pathology: Genitourinary. In *Diagnostic Pathology: Genitourinary*. https://doi.org/10.1016/B978-0-323-37714-0.50202-9

Baig, F. A., Hamid, A., Mirza, T., & Syed, S. (2015). Ductal and acinar adenocarcinoma of Prostatic: Morphological and immunohistochemical characterization. *Oman Medical Journal*, *30*(3), 162–166. https://doi.org/10.5001/omj.2015.36

Bott Simon RJ, & Ng Keng Lim. (2021). Prostatic Cancer. In *Exon Publications*.

Chen, Y., Xu, H., Shi, Q., Gu, M., Wan, X., Chen, Q., & Wang, Z. (2019). Hypoxia-inducible factor 1α (HIF-1α) mediates the epithelial-mesenchymal transition in benign prostatic hyperplasia. In *International journal of clinical and experimental pathology* (Vol. 12, Issue 1, pp. 295–304). http://www.ncbi.nlm.nih.gov/pubmed/31933745%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6944022

Cheng, L., MacLennan, G. T., & Bostwick, D. G. (2020). Urologic Surgical Pathology. In *Urologic Surgical Pathology*. https://doi.org/10.1016/C2016-0-03492-7

Collin, L. J., Maliniak, M. L., Cronin-Fenton, D. P., Ahern, T. P., Christensen, K. B., Ulrichsen, S. P., Damkier, P., Hamilton-Dutoit, S., Yacoub, R., Christiansen, P. M., Sørensen, H. T., & Lash, T. L. (2021). Hypoxia-inducible factor-1α expression and breast cancer recurrence in a Danish population-based case control study. *Breast Cancer Research*, *23*(1). https://doi.org/10.1186/s13058-021-01480-1

Curtis, K. K., Wong, W. W., & Ross, H. J. (2016). Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. *Critical Reviews in Oncology/Hematology*, *103*, 86–98. https://doi.org/10.1016/j.critrevonc.2016.05.005

DeVita et all. (2018). *Cancer: Principles & Practice of Oncology,* (11th ed.). Wolters Kluwer Health. https://www.ptonline.com/articles/how-to-get-better-mfi-results

Du, Z., Fujiyama, C., Chen, Y., & Masaki, Z. (2003). Expression of hypoxia-inducible factor 1α in human normal, benign, and malignant Prostatic tissue. In *Chinese Medical Journal* (Vol. 116, Issue 12, pp. 1936–1939).

Egevad, L., Delahunt, B., Furusato, B., Tsuzuki, T., Yaxley, J., & Samaratunga, H. (2021). Benign mimics of Prostatic cancer. *Pathology*, *53*(1), 26–35. https://doi.org/10.1016/j.pathol.2020.08.006

Epstein, J. I. (2012). Diagnosis of limited adenocarcinoma of the Prostatic. *Histopathology*, *60*(1), 28–40. https://doi.org/10.1111/j.1365-2559.2011.03990.x

Epstein, J. I. (2018). Prostatic cancer grading: a decade after the 2005 modified system. *Modern Pathology*, *31*(S1), 47–63. https://doi.org/10.1038/modpathol.2017.133

Erosschenko, V. & D. F. (2013). *DiFiore's atlas of histology with functional correlations*.

Frost, J., Frost, M., Batie, M., Jiang, H., & Rocha, S. (2021). Roles of hif and 2-oxoglutarate-dependent dioxygenases in controlling gene expression in hypoxia. In *Cancers* (Vol. 13, Issue 2). https://doi.org/10.3390/cancers13020350

Garg, M., Kaur, G., Malhotra, V., & Garg, R. (2013). Histopathological spectrum of 364 prostatic specimens including immunohistochemistry with special reference to grey zone lesions. *Prostatic International*, *1*(4), 146–151. https://doi.org/10.12954/pi.13026

Globocan. (2020). International Agency for Research on Cancer. *Globocan*, *23*(7), 323–326.

Hammerich, K. H., Ayala, G. E., & Wheeler, T. M. (2008). Anatomy of the Prostatic gland and surgical pathology of Prostatic cancer. *Prostatic Cancer*, *November*, 1–14. https://doi.org/10.1017/CBO9780511551994.003

Humphrey et all. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs. In *Clinical Equine Oncology* (4th ed.). Lyon. https://doi.org/10.1016/B978-0-7020-4266-9.00036-2

Humphrey, P. A. (2017). *Histopathology of Prostatic Cancer*. 1–22.

Ikeda, H., & Kakeya, H. (2021). Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy. *Journal of Antibiotics*, *74*(10), 687–695. https://doi.org/10.1038/s41429-021-00451-0

Jinna, N., Rida, P., Smart, M., LaBarge, M., Jovanovic-Talisman, T., Natarajan, R., & Seewaldt, V. (2022). Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. *International Journal of Molecular Sciences*, *23*(16). https://doi.org/10.3390/ijms23168844

Kementrian Kesehatan Republik, I. (2018). PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA KANKER PROSTAT.

*Kementrian Kesehatan Republik Indonesia*, *63*(2), 1–3. http://forschungsunion.de/pdf/industrie_4_0_umsetzungsempfehlungen.pdf%0Ahttps://www.dfki.de/fileadmin/user_upload/import/9744_171012-KI-Gipfelpapier-online.pdf%0Ahttps://www.bitkom.org/sites/default/files/ pdf/Presse/Anhaenge-an-PIs/ 2018/180607 -Bitkom

Kimbro, K. S., & Simons, J. W. (2006). Hypoxia-inducible factor-1 in human breast and Prostatic cancer. *Endocrine-Related Cancer*, *13*(3), 739–749. https://doi.org/10.1677/erc.1.00728

Kozal, K., & Krześlak, A. (2022). The Role of Hypoxia-Inducible Factor Isoforms in Breast Cancer and Perspectives on Their Inhibition in Therapy. *Cancers*, *14*(18). https://doi.org/10.3390/cancers14184518

Kryvenko, O. N., & Epstein, J. I. (2016). Prostatic cancer grading: A decade after the 2005 modified gleason grading system. *Archives of Pathology and Laboratory Medicine*, *140*(10), 1153–1156. https://doi.org/10.5858/arpa.2015-0487-SA

Kumar, V., Abbas, A., Aster, J., & Turner, J. (2021). Robbins & Cotran Pathologic Basis of Disease Tenth Edition. In *Elsevier*.

Lee, S. H., Golinska, M., & Griffiths, J. R. (2021). Hif-1-independent mechanisms regulating metabolic adaptation in hypoxic cancer cells. *Cells*, *10*(9). https://doi.org/10.3390/cells10092371

Magers, M., Kunju, L. P., & Wu, A. (2015). Intraductal carcinoma of the Prostatic morphologic features, differential diagnoses, significance, and reporting practices. *Archives of Pathology and Laboratory Medicine*, *139*(10), 1234–1241. https://doi.org/10.5858/arpa.2015-0206-RA

Marignol, L., Coffey, M., Lawler, M., & Hollywood, D. (2008). Hypoxia in Prostatic cancer: A powerful shield against tumour destruction? *Cancer Treatment Reviews*, *34*(4), 313–327. https://doi.org/10.1016/j.ctrv.2008.01.006

Masoud, G. N., & Li, W. (2015). HIF-1α pathway: Role, regulation and intervention for cancer therapy. *Acta Pharmaceutica Sinica B*, *5*(5), 378–389. https://doi.org/10.1016/j.apsb.2015.05.007

Masoud, G. N., & Lin, W. (2015). *Jalur HIF-1ÿ : peran , regulasi , dan intervensi untuk terapi kanker*. *5*(5), 378–389.

Murgod, P. S., Doshi, P. R., Nisal, A. R., & Nimbargi, R. C. (2021). Histomorphological Mimickers of benign prostatic lesions with prostatic adenocarcinoma. *Journal of Pathology of Nepal*, *11*(1), 1859–1863. https://doi.org/10.3126/jpn.v10i2.29009

Putriyuni, A., & Hilbertina, N. (2015). Adenokarsinoma Prostat: Penilaian Prognostik Dan Derajat Histopatologi. *Majalah Kedokteran Andalas*, *37*(2), 93. https://doi.org/10.22338/mka.v37.i2.p93-100.2014

Rahman, T. (2016). Benign Prostatic Hyperplasia: Review and Update on Etiopathogenesis and Treatment Modalities. *J Urol Res*, *3*(5), 1063. https://www.jscimedcentral.com/Urology/urology-3-1063.pdf

Rosai, J. (2018). Rosai and Ackerman's surgical pathology. In G. Tallini & T. J. Giordano (Eds.), *Rosai and Ackerman's surgical pathology* (8th ed., pp. 289–366). Elsevier Health Sciences.

Sehn, J. K. (2018). Prostatic Cancer Pathology: Recent Updates and Controversies. *Missouri Medicine*, *115*(2), 151–155.

Semenza, G. L. (2001). HIF-1, O2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus. *Cell*, *107*(1), 1–3. https://doi.org/10.1016/S0092-8674(01)00518-9

Semenza, G. L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. *Science's STKE : Signal Transduction Knowledge Environment*, *2007*(407), 9–12. https://doi.org/10.1126/stke.4072007cm8

Sun, X., Huang, Q., Peng, F., Wang, J., Zhao, W., & Guo, G. (2021). Expression and Clinical Significance of HKII and HIF-1α in Grade Groups of Prostatic Cancer. *Frontiers in Genetics*, *12*(June), 1–8. https://doi.org/10.3389/fgene.2021.680928

Tran, M. G. B., Bibby, B. A. S., Yang, L., Lo, F., Warren, A. Y., Shukla, D., Osborne, M., Hadfield, J., Carroll, T., Stark, R., Scott, H., Ramos-Montoya, A., Massie, C., Maxwell, P., West, C. M. L., Mills, I. G., & Neal, D. E. (2020). Independence of HIF1a and androgen signaling pathways in Prostatic cancer. *BMC Cancer*, *20*(1), 1–12. https://doi.org/10.1186/s12885-020-06890-6

Udensi, U. K., & Tchounwou, P. B. (2016). Oxidative stress in Prostatic hyperplasia and carcinogenesis. *Journal of Experimental and Clinical Cancer Research*, *35*(1), 1–19. https://doi.org/10.1186/s13046-016-0418-8

Weidemann, A., & Johnson, R. S. (2008). Biology of HIF-1α. *Cell Death and Differentiation*, *15*(4), 621–627. https://doi.org/10.1038/cdd.2008.12

Zhang, Q., Han, Z., Zhu, Y., Chen, J., & Li, W. (2021). Role of hypoxia inducible factor-1 in cancer stem cells (Review). *Molecular Medicine Reports*, *23*(1), 1–14. https://doi.org/10.3892/mmr.2020.11655

Zhang, Z., Yao, L., Yang, J., Wang, Z., & Du, G. (2018). PI3K/Akt and HIF-1 signaling pathway in hypoxia-ischemia (Review). *Molecular Medicine Reports*, *18*(4), 3547–3554. https://doi.org/10.3892/mmr.2018.9375

Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., & Simons, J. W. (1999). Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. In *Cancer Research* (Vol. 59, Issue 22, pp. 5830–5835).

Zhong, H., Hanrahan, C., Van der Poel, H., & Simons, J. W. (2001). Hypoxia-inducible factor 1α and 1β proteins share common signaling pathways in human Prostatic cancer cells. *Biochemical and Biophysical Research Communications*, *284*(2), 352–356. https://doi.org/10.1006/bbrc.2001.4981

Zhong, H., Semenza, G. L., Simons, J. W., & De Marzo, A. M. (2004). Up-regulation of hypoxia-inducible factor 1α is an early event in Prostatic carcinogenesis. In *Cancer Detection and Prevention* (Vol. 28, Issue 2, pp. 88–93). https://doi.org/10.1016/j.cdp.2003.12.009

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,.MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

## REKOMENDASI PERSETUJUAN ETIK

Nomor : 619/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 4 September 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | |
|---|---|---|---|
| No Protokol | UH23080542 | No Sponsor | |
| Peneliti Utama | **dr. Asmirani Sudin** | Sponsor | |
| Judul Peneliti | Ekspresi Hypoxia Inducible Factor-1 Alpha (HIF-1a) Pada Neoplasma Prostat | | |
| No Versi Protokol | **1** | Tanggal Versi | **31 Juli 2023** |
| No Versi PSP | | Tanggal Versi | |
| Tempat Penelitian | RS Universitas Hasanuddin Makassar | | |
| Jenis Review | ☐ Exempted<br>☒ Expedited<br>☐ Fullboard Tanggal | Masa Berlaku **4 September 2023** sampai **4 September 2024** | Frekuensi review lanjutan |
| Ketua KEP Universitas Hasanuddin | Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)** | Tanda tangan | |
| Sekretaris KEP Universitas Hasanuddin | Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)** | Tanda tangan | |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Ekspresi HIF 1 Alpha pada BPH, PIN, LGAP, HGAP

| No | Usia (thn) | Usia | Kelompok | Intensitas | % Proporsi | Proporsi | Hasil IR | IR | Ket IR | Keterangan |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 70 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | Negatif | |
| 2 | 54 | 1 | 1 | 1 | 30 | 2 | 2 | 1 | Lemah | Usia: |
| 3 | 59 | 1 | 1 | 1 | 30 | 2 | 2 | 1 | Lemah | 1 = <70 tahun |
| 4 | 64 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | Negatif | 2 = ≥ 70 tahun |
| 5 | 73 | 2 | 1 | 1 | 20 | 1 | 1 | 1 | Lemah | |
| 6 | 63 | 1 | 1 | 1 | 30 | 2 | 2 | 1 | Lemah | |
| 7 | 75 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | Negatif | Kelompok: |
| 8 | 83 | 2 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | 1 = BPH |
| 9 | 82 | 2 | 1 | 1 | 20 | 1 | 1 | 1 | Lemah | 2 = PIN |
| 10 | 60 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | Negatif | 3 = Low Grade Adenocarcinoma Prostat |
| 11 | 66 | 1 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | 4 = High Grade Adenocarcinoma Prostat |
| 12 | 74 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | Negatif | |
| 13 | 75 | 2 | 1 | 1 | 15 | 1 | 1 | 1 | Lemah | Intensitas: |
| 14 | 98 | 2 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | 0 = Tidak ada sel tumor yang terwarnai |
| 15 | 69 | 1 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | 1 = Lemah |
| 16 | 63 | 1 | 1 | 1 | 15 | 1 | 1 | 1 | Lemah | 2 = Sedang |
| 17 | 69 | 1 | 1 | 1 | 65 | 3 | 3 | 1 | Lemah | 3 = Kuat |
| 18 | 61 | 1 | 1 | 1 | 30 | 2 | 2 | 1 | Lemah | |
| 19 | 61 | 1 | 1 | 2 | 55 | 3 | 6 | 2 | Kuat | |
| 20 | 63 | 1 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | Proporsi Area Terwarnai: |
| 21 | 66 | 1 | 1 | 1 | 15 | 1 | 1 | 1 | Lemah | 0 = tidak ada sel tumor yang terwarnai sampai <5% |
| 22 | 52 | 1 | 1 | 1 | 10 | 1 | 1 | 1 | Lemah | 1 = area terwarnai 5% sampai 25% |
| 23 | 69 | 1 | 1 | 1 | 30 | 2 | 2 | 1 | Lemah | 2 = area terwarnai >25% sampai 50% |
| 24 | 98 | 2 | 1 | 1 | 15 | 1 | 1 | 1 | Lemah | 3 = area terwarnai >50% |
| 25 | 63 | 1 | 1 | 1 | 15 | 1 | 1 | 1 | Lemah | |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 70 | 2 | 2 | 2 | 55 | 3 | 6 | 2 | Kuat | |
| 27 | 54 | 1 | 2 | 3 | 35 | 2 | 6 | 2 | Kuat | IR Score : Intensitas x Proporsi area terwarnai |
| 28 | 59 | 1 | 2 | 3 | 60 | 3 | 9 | 2 | Kuat | Negatif (0) = 0 |
| 29 | 64 | 1 | 2 | 2 | 60 | 3 | 6 | 2 | Kuat | Lemah (+1) = 1-3 |
| 30 | 73 | 2 | 2 | 3 | 55 | 3 | 9 | 2 | Kuat | Kuat (+2) = 4-9 |
| 31 | 63 | 1 | 2 | 2 | 60 | 3 | 6 | 2 | Kuat | |
| 32 | 75 | 2 | 2 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 33 | 83 | 2 | 2 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 34 | 82 | 2 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 35 | 60 | 1 | 2 | 3 | 30 | 2 | 6 | 2 | Kuat | |
| 36 | 66 | 1 | 2 | 3 | 30 | 2 | 6 | 2 | Kuat | |
| 37 | 74 | 2 | 2 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 38 | 75 | 2 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 39 | 98 | 2 | 2 | 3 | 30 | 2 | 6 | 2 | Kuat | |
| 40 | 69 | 1 | 2 | 2 | 15 | 1 | 2 | 1 | Lemah | |
| 41 | 63 | 1 | 2 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 42 | 69 | 1 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 43 | 61 | 1 | 2 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 44 | 61 | 1 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 45 | 63 | 1 | 2 | 2 | 60 | 2 | 4 | 2 | Kuat | |
| 46 | 66 | 1 | 2 | 2 | 20 | 1 | 2 | 2 | Kuat | |
| 47 | 52 | 1 | 2 | 2 | 15 | 1 | 2 | 1 | Lemah | |
| 48 | 69 | 1 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 49 | 98 | 2 | 2 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 50 | 63 | 1 | 2 | 3 | 40 | 2 | 6 | 2 | Kuat | |
| 51 | 68 | 1 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 52 | 81 | 2 | 3 | 3 | 65 | 3 | 9 | 2 | Kuat | |
| 53 | 75 | 2 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 54 | 72 | 2 | 3 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 55 | 71 | 2 | 3 | 2 | 30 | 2 | 4 | 2 | Kuat | |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 56 | 67 | 1 | 3 | 3 | 55 | 3 | 9 | 2 | Kuat | |
| 57 | 48 | 1 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 58 | 69 | 1 | 3 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 59 | 77 | 2 | 3 | 1 | 35 | 2 | 2 | 1 | Lemah | |
| 60 | 61 | 1 | 3 | 2 | 35 | 2 | 4 | 2 | Kuat | |
| 61 | 81 | 2 | 3 | 3 | 30 | 2 | 6 | 2 | Kuat | |
| 62 | 52 | 1 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 63 | 65 | 1 | 3 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 64 | 74 | 2 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 65 | 73 | 2 | 3 | 3 | 65 | 3 | 9 | 2 | Kuat | |
| 66 | 66 | 1 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 67 | 60 | 1 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 68 | 77 | 2 | 3 | 3 | 55 | 3 | 9 | 2 | Kuat | |
| 69 | 82 | 2 | 3 | 2 | 30 | 2 | 4 | 2 | Kuat | |
| 70 | 86 | 2 | 3 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 71 | 62 | 1 | 3 | 2 | 55 | 3 | 6 | 2 | Kuat | |
| 72 | 54 | 1 | 3 | 3 | 30 | 2 | 6 | 2 | Kuat | |
| 73 | 79 | 2 | 3 | 3 | 60 | 3 | 9 | 2 | Kuat | |
| 74 | 55 | 1 | 3 | 2 | 55 | 3 | 6 | 2 | Kuat | |
| 75 | 63 | 1 | 3 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 76 | 68 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 77 | 68 | 1 | 4 | 3 | 40 | 2 | 6 | 2 | Kuat | |
| 78 | 71 | 2 | 4 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 79 | 69 | 1 | 4 | 3 | 75 | 3 | 9 | 2 | Kuat | |
| 80 | 62 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 81 | 52 | 1 | 4 | 3 | 75 | 3 | 9 | 2 | Kuat | |
| 82 | 73 | 2 | 4 | 3 | 75 | 3 | 9 | 2 | Kuat | |
| 83 | 60 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 84 | 65 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 85 | 65 | 1 | 4 | 2 | 75 | 3 | 6 | 2 | Kuat | |

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 86 | 67 | 1 | 4 | 2 | 75 | 3 | 6 | 2 | Kuat | |
| 87 | 56 | 1 | 4 | 3 | 40 | 2 | 6 | 2 | Kuat | |
| 88 | 78 | 2 | 4 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 89 | 66 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 90 | 67 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 91 | 60 | 1 | 4 | 2 | 70 | 3 | 6 | 2 | Kuat | |
| 92 | 73 | 2 | 4 | 3 | 40 | 2 | 6 | 2 | Kuat | |
| 93 | 72 | 2 | 4 | 2 | 75 | 3 | 6 | 2 | Kuat | |
| 94 | 63 | 1 | 4 | 2 | 80 | 3 | 6 | 2 | Kuat | |
| 95 | 62 | 1 | 4 | 3 | 45 | 2 | 6 | 2 | Kuat | |
| 96 | 70 | 2 | 4 | 2 | 70 | 3 | 6 | 2 | Kuat | |
| 97 | 84 | 2 | 4 | 2 | 75 | 3 | 6 | 2 | Kuat | |
| 98 | 54 | 1 | 4 | 3 | 70 | 3 | 9 | 2 | Kuat | |
| 99 | 65 | 1 | 4 | 3 | 80 | 3 | 9 | 2 | Kuat | |
| 100 | 59 | 1 | 4 | 3 | 40 | 2 | 6 | 2 | Kuat | |

**Frequencies**

**Notes**

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:52:02 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | User-defined missing values are treated as missing. |
| | Cases Used | Statistics are based on all cases with valid data. |
| Syntax | | FREQUENCIES VARIABLES=Kat_Usia Kelompok Intensitas Kat_Proporsi IR IR_2 /ORDER=ANALYSIS. |
| Resources | Processor Time | 00:00:00.03 |
| | Elapsed Time | 00:00:00.02 |

[DataSet42] D:\Office\Statistics\Data dr Mimi.sav

**Statistics**

| | | Kat_Usia | Kelompok | Intensitas | Kat_Proporsi | IR | IR_2 |
|---|---|---|---|---|---|---|---|
| N | Valid | 100 | 100 | 100 | 100 | 100 | 100 |
| | Missing | 0 | 0 | 0 | 0 | 0 | 0 |

**Frequency Table**

**Kat_Usia**

| | | Frequency | Percent | Valid Percent | Cumulative Percent |
|---|---|---|---|---|---|
| Valid | < 70 tahun | 63 | 63.0 | 63.0 | 63.0 |
| | ≥ 70 tahun | 37 | 37.0 | 37.0 | 100.0 |
| | Total | 100 | 100.0 | 100.0 | |

**Kelompok**

| | | Frequency | Percent | Valid Percent | Cumulative Percent |
|---|---|---|---|---|---|
| Valid | BPH | 25 | 25.0 | 25.0 | 25.0 |
| | PIN | 25 | 25.0 | 25.0 | 50.0 |
| | Low Grade Adenocarcinoma Prostat | 25 | 25.0 | 25.0 | 75.0 |
| | High Grade Adenocarcinoma Prostat | 25 | 25.0 | 25.0 | 100.0 |
| | Total | 100 | 100.0 | 100.0 | |

**Intensitas**

| | | Frequency | Percent | Valid Percent | Cumulative Percent |
|---|---|---|---|---|---|
| Valid | Tidak ada sel tumor yang terwarnai | 5 | 5.0 | 5.0 | 5.0 |
| | Lemah | 20 | 20.0 | 20.0 | 25.0 |
| | Sedang | 31 | 31.0 | 31.0 | 56.0 |
| | Kuat | 44 | 44.0 | 44.0 | 100.0 |
| | Total | 100 | 100.0 | 100.0 | |

**Kat_Proporsi**

| | | Frequency | Percent | Valid Percent | Cumulative Percent |
|---|---|---|---|---|---|
| Valid | tidak ada sel tumor yang terwarnai sampai <5% | 5 | 5.0 | 5.0 | 5.0 |
| | area terwarnai 5% sampai 25% | 16 | 16.0 | 16.0 | 21.0 |
| | area terwarnai >25% sampai 50% | 33 | 33.0 | 33.0 | 54.0 |
| | area terwarnai >50% | 46 | 46.0 | 46.0 | 100.0 |
| | Total | 100 | 100.0 | 100.0 | |

**IR**

| | | Frequency | Percent | Valid Percent | Cumulative Percent |
|---|---|---|---|---|---|
| Valid | Negatif | 5 | 5.0 | 5.0 | 5.0 |
| | Lemah | 22 | 22.0 | 22.0 | 27.0 |
| | Kuat | 73 | 73.0 | 73.0 | 100.0 |
| | Total | 100 | 100.0 | 100.0 | |

```
MEANS TABLES=Usia Proporsi Hasil_IR
  /CELLS=MEAN STDDEV MEDIAN MIN MAX.
```

**Means**

**Notes**

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:52:24 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | For each dependent variable in a table, user-defined missing values for the dependent and all grouping variables are treated as missing. |
| | Cases Used | Cases used for each table have no missing values in any independent variable, and not all dependent variables have missing values. |
| Syntax | | MEANS TABLES=Usia Proporsi Hasil_IR<br>/CELLS=MEAN STDDEV MEDIAN MIN MAX. |
| Resources | Processor Time | 00:00:00.00 |
| | Elapsed Time | 00:00:00.02 |

## Case Processing Summary

| | Cases | | | | | |
|---|---|---|---|---|---|---|
| | Included | | Excluded | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Usia | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Proporsi | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Hasil_IR | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |

## Report

| | Usia | Proporsi | Hasil_IR |
|---|---|---|---|
| Mean | 68.2700 | 44.6000 | 5.3200 |
| Std. Deviation | 10.18104 | 24.08612 | 3.11361 |
| Median | 67.0000 | 40.0000 | 6.0000 |
| Minimum | 48.00 | .00 | .00 |
| Maximum | 98.00 | 80.00 | 9.00 |

```
CROSSTABS
  /TABLES=Kat_Usia Intensitas Kat_Proporsi IR IR_2 BY Kelompok
  /FORMAT=AVALUE TABLES
  /STATISTICS=CHISQ
  /CELLS=COUNT COLUMN
  /COUNT ROUND CELL.
```

## Crosstabs

### Notes

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:52:53 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | User-defined missing values are treated as missing. |
| | Cases Used | Statistics for each table are based on all the cases with valid data in the specified range(s) for all variables in each table. |

| | | |
|---|---|---|
| Syntax | | CROSSTABS /TABLES=Kat_Usia Intensitas Kat_Proporsi IR IR_2 BY Kelompok /FORMAT=AVALUE TABLES /STATISTICS=CHISQ /CELLS=COUNT COLUMN /COUNT ROUND CELL. |
| Resources | Processor Time | 00:00:00.02 |
| | Elapsed Time | 00:00:00.03 |
| | Dimensions Requested | 2 |
| | Cells Available | 524245 |

**Intensitas * Kelompok**

**Crosstab**

| | | | Kelompok | | | | |
|---|---|---|---|---|---|---|---|
| | | | BPH | PIN | Low Grade Adenocarcinoma Prostat | High Grade Adenocarcinoma Prostat | Total |
| Intensitas | Tidak ada sel tumor yang terwarnai | Count | 5 | 0 | 0 | 0 | 5 |
| | | % within Kelompok | 20.0% | 0.0% | 0.0% | 0.0% | 5.0% |
| | Lemah | Count | 19 | 0 | 1 | 0 | 20 |
| | | % within Kelompok | 76.0% | 0.0% | 4.0% | 0.0% | 20.0% |
| | Sedang | Count | 1 | 17 | 6 | 7 | 31 |
| | | % within Kelompok | 4.0% | 68.0% | 24.0% | 28.0% | 31.0% |
| | Kuat | Count | 0 | 8 | 18 | 18 | 44 |
| | | % within Kelompok | 0.0% | 32.0% | 72.0% | 72.0% | 44.0% |
| Total | | Count | 25 | 25 | 25 | 25 | 100 |
| | | % within Kelompok | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

**Chi-Square Tests**

| | Value | df | Asymptotic Significance (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 105.514[a] | 9 | .000 |
| Likelihood Ratio | 109.853 | 9 | .000 |
| Linear-by-Linear Association | 54.303 | 1 | .000 |
| N of Valid Cases | 100 | | |

a. 4 cells (25.0%) have expected count less than 5. The minimum expected count is 1.25.

**Kat_Proporsi * Kelompok**

**Crosstab**

| | | | Kelompok | | | | Total |
|---|---|---|---|---|---|---|---|
| | | | BPH | PIN | Low Grade Adenocarcinoma Prostat | High Grade Adenocarcinoma Prostat | |
| Kat_Proporsi | tidak ada sel tumor yang terwarnai sampai <5% | Count | 5 | 0 | 0 | 0 | 5 |
| | | % within Kelompok | 20.0% | 0.0% | 0.0% | 0.0% | 5.0% |
| | area terwarnai 5% sampai 25% | Count | 13 | 3 | 0 | 0 | 16 |
| | | % within Kelompok | 52.0% | 12.0% | 0.0% | 0.0% | 16.0% |
| | area terwarnai >25% sampai 50% | Count | 5 | 16 | 7 | 5 | 33 |
| | | % within Kelompok | 20.0% | 64.0% | 28.0% | 20.0% | 33.0% |
| | area terwarnai >50% | Count | 2 | 6 | 18 | 20 | 46 |
| | | % within Kelompok | 8.0% | 24.0% | 72.0% | 80.0% | 46.0% |
| Total | | Count | 25 | 25 | 25 | 25 | 100 |
| | | % within Kelompok | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |

**Chi-Square Tests**

| | Value | df | Asymptotic Significance (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 73.965[a] | 9 | .000 |
| Likelihood Ratio | 75.123 | 9 | .000 |
| Linear-by-Linear Association | 48.342 | 1 | .000 |
| N of Valid Cases | 100 | | |

a. 8 cells (50.0%) have expected count less than 5. The minimum expected count is 1.25.

**IR * Kelompok**

**Crosstab**

| | | | Kelompok | | | | Total |
|---|---|---|---|---|---|---|---|
| | | | BPH | PIN | Low Grade Adenocarcinoma Prostat | High Grade Adenocarcinoma Prostat | |
| IR | Negatif | Count | 5 | 0 | 0 | 0 | 5 |
| | | % within Kelompok | 20.0% | 0.0% | 0.0% | 0.0% | 5.0% |
| | Lemah | Count | 19 | 2 | 1 | 0 | 22 |
| | | % within Kelompok | 76.0% | 8.0% | 4.0% | 0.0% | 22.0% |
| | Kuat | Count | 1 | 23 | 24 | 25 | 73 |
| | | % within Kelompok | 4.0% | 92.0% | 96.0% | 100.0% | 73.0% |
| Total | | Count | 25 | 25 | 25 | 25 | 100 |
| | | % within Kelompok | 100.0% | 100.0 % | 100.0% | 100.0% | 100.0% |

**Chi-Square Tests**

| | Value | df | Asymptotic Significance (2-sided) |
|---|---|---|---|
| Pearson Chi-Square | 81.395[a] | 6 | .000 |
| Likelihood Ratio | 87.230 | 6 | .000 |
| Linear-by-Linear Association | 48.278 | 1 | .000 |
| N of Valid Cases | 100 | | |

a. 4 cells (33.3%) have expected count less than 5. The minimum expected count is 1.25.

**Means**

## Notes

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:53:06 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | For each dependent variable in a table, user-defined missing values for the dependent and all grouping variables are treated as missing. |
| | Cases Used | Cases used for each table have no missing values in any independent variable, and not all dependent variables have missing values. |
| Syntax | | MEANS TABLES=Usia Proporsi Hasil_IR BY Kelompok /CELLS=MEAN STDDEV MEDIAN MIN MAX. |
| Resources | Processor Time | 00:00:00.02 |
| | Elapsed Time | 00:00:00.02 |

## Case Processing Summary

| | Cases | | | | | |
|---|---|---|---|---|---|---|
| | Included | | Excluded | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Usia * Kelompok | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Proporsi * Kelompok | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Hasil_IR * Kelompok | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |

**Report**

| Kelompok | | Usia | Proporsi | Hasil_IR |
|---|---|---|---|---|
| BPH | Mean | 69.2000 | 17.8000 | 1.2800 |
| | Std. Deviation | 11.49275 | 16.27114 | 1.24231 |
| | Median | 66.0000 | 15.0000 | 1.0000 |
| | Minimum | 52.00 | .00 | .00 |
| | Maximum | 98.00 | 65.00 | 6.00 |
| PIN | Mean | 69.2000 | 38.6000 | 5.0000 |
| | Std. Deviation | 11.49275 | 15.03607 | 1.97906 |
| | Median | 66.0000 | 35.0000 | 4.0000 |
| | Minimum | 52.00 | 15.00 | 2.00 |
| | Maximum | 98.00 | 70.00 | 9.00 |
| Low Grade Adenocarcinoma Prostat | Mean | 68.7200 | 53.2000 | 7.4400 |
| | Std. Deviation | 10.15103 | 14.64013 | 2.27450 |
| | Median | 69.0000 | 60.0000 | 9.0000 |
| | Minimum | 48.00 | 30.00 | 2.00 |
| | Maximum | 86.00 | 70.00 | 9.00 |
| High Grade Adenocarcinoma Prostat | Mean | 65.9600 | 68.8000 | 7.5600 |
| | Std. Deviation | 7.26567 | 14.66856 | 1.52971 |
| | Median | 66.0000 | 75.0000 | 9.0000 |
| | Minimum | 52.00 | 40.00 | 6.00 |
| | Maximum | 84.00 | 80.00 | 9.00 |
| Total | Mean | 68.2700 | 44.6000 | 5.3200 |
| | Std. Deviation | 10.18104 | 24.08612 | 3.11361 |
| | Median | 67.0000 | 40.0000 | 6.0000 |
| | Minimum | 48.00 | .00 | .00 |
| | Maximum | 98.00 | 80.00 | 9.00 |

```
EXAMINE VARIABLES=Usia Proporsi Hasil_IR
  /PLOT BOXPLOT STEMLEAF NPPLOT
  /COMPARE GROUPS
  /STATISTICS DESCRIPTIVES
  /CINTERVAL 95
  /MISSING LISTWISE
  /NOTOTAL.
```

**Explore**

## Notes

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:53:21 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | User-defined missing values for dependent variables are treated as missing. |
| | Cases Used | Statistics are based on cases with no missing values for any dependent variable or factor used. |
| Syntax | | EXAMINE VARIABLES=Usia Proporsi Hasil_IR<br>/PLOT BOXPLOT STEMLEAF NPPLOT<br>/COMPARE GROUPS<br>/STATISTICS DESCRIPTIVES<br>/CINTERVAL 95<br>/MISSING LISTWISE<br>/NOTOTAL. |
| Resources | Processor Time | 00:00:00.72 |
| | Elapsed Time | 00:00:00.91 |

## Case Processing Summary

| | Cases | | | | | |
|---|---|---|---|---|---|---|
| | Valid | | Missing | | Total | |
| | N | Percent | N | Percent | N | Percent |
| Usia | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Proporsi | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |
| Hasil_IR | 100 | 100.0% | 0 | 0.0% | 100 | 100.0% |

**Descriptives**

| | | | Statistic | Std. Error |
|---|---|---|---|---|
| Usia | Mean | | 68.2700 | 1.01810 |
| | 95% Confidence Interval for Mean | Lower Bound | 66.2499 | |
| | | Upper Bound | 70.2901 | |
| | 5% Trimmed Mean | | 67.7000 | |
| | Median | | 67.0000 | |
| | Variance | | 103.654 | |
| | Std. Deviation | | 10.18104 | |
| | Minimum | | 48.00 | |
| | Maximum | | 98.00 | |
| | Range | | 50.00 | |
| | Interquartile Range | | 11.75 | |
| | Skewness | | .860 | .241 |
| | Kurtosis | | 1.233 | .478 |
| Proporsi | Mean | | 44.6000 | 2.40861 |
| | 95% Confidence Interval for Mean | Lower Bound | 39.8208 | |
| | | Upper Bound | 49.3792 | |
| | 5% Trimmed Mean | | 45.1111 | |
| | Median | | 40.0000 | |
| | Variance | | 580.141 | |
| | Std. Deviation | | 24.08612 | |
| | Minimum | | .00 | |
| | Maximum | | 80.00 | |
| | Range | | 80.00 | |
| | Interquartile Range | | 38.75 | |
| | Skewness | | -.138 | .241 |
| | Kurtosis | | -1.190 | .478 |
| Hasil_IR | Mean | | 5.3200 | .31136 |
| | 95% Confidence Interval for Mean | Lower Bound | 4.7022 | |
| | | Upper Bound | 5.9378 | |
| | 5% Trimmed Mean | | 5.4111 | |
| | Median | | 6.0000 | |
| | Variance | | 9.695 | |
| | Std. Deviation | | 3.11361 | |
| | Minimum | | .00 | |
| | Maximum | | 9.00 | |

| | | | |
|---|---|---|---|
| | Range | 9.00 | |
| | Interquartile Range | 7.00 | |
| | Skewness | -.196 | .241 |
| | Kurtosis | -1.315 | .478 |

**Kruskal-Wallis Test**

**Ranks**

| | Kelompok | N | Mean Rank |
|---|---|---|---|
| Usia | BPH | 25 | 51.34 |
| | PIN | 25 | 51.34 |
| | Low Grade Adenocarcinoma Prostat | 25 | 54.40 |
| | High Grade Adenocarcinoma Prostat | 25 | 44.92 |
| | Total | 100 | |
| Proporsi | BPH | 25 | 18.48 |
| | PIN | 25 | 42.86 |
| | Low Grade Adenocarcinoma Prostat | 25 | 58.64 |
| | High Grade Adenocarcinoma Prostat | 25 | 82.02 |
| | Total | 100 | |
| Hasil_IR | BPH | 25 | 14.80 |
| | PIN | 25 | 46.66 |
| | Low Grade Adenocarcinoma Prostat | 25 | 69.72 |
| | High Grade Adenocarcinoma Prostat | 25 | 70.82 |
| | Total | 100 | |

**Test Statistics[a,b]**

| | Usia | Proporsi | Hasil_IR |
|---|---|---|---|
| Kruskal-Wallis H | 1.422 | 64.331 | 65.093 |
| df | 3 | 3 | 3 |
| Asymp. Sig. | .700 | .000 | .000 |

a. Kruskal Wallis Test

b. Grouping Variable: Kelompok

```
DATASET ACTIVATE DataSet42.
NPAR TESTS
  /M-W= Usia Proporsi Hasil_IR BY Kelompok(1 2)
  /MISSING ANALYSIS.
```

**NPar Tests**

**Notes**

| | | |
|---|---|---|
| Output Created | | 27-OCT-2023 20:54:35 |
| Comments | | |
| Input | Data | D:\Office\Statistics\Data dr Mimi.sav |
| | Active Dataset | DataSet42 |
| | Filter | <none> |
| | Weight | <none> |
| | Split File | <none> |
| | N of Rows in Working Data File | 100 |
| Missing Value Handling | Definition of Missing | User-defined missing values are treated as missing. |
| | Cases Used | Statistics for each test are based on all cases with valid data for the variable(s) used in that test. |
| Syntax | | NPAR TESTS /M-W= Usia Proporsi Hasil_IR BY Kelompok(1 2) /MISSING ANALYSIS. |
| Resources | Processor Time | 00:00:00.02 |
| | Elapsed Time | 00:00:00.02 |
| | Number of Cases Allowed[a] | 349525 |

a. Based on availability of workspace memory.

**Mann-Whitney Test**

**Ranks**

| | Kelompok | N | Mean Rank | Sum of Ranks |
|---|---|---|---|---|
| Usia | BPH | 25 | 25.50 | 637.50 |
| | PIN | 25 | 25.50 | 637.50 |

| | | | | |
|---|---|---|---|---|
| | Total | 50 | | |
| Proporsi | BPH | 25 | 16.42 | 410.50 |
| | PIN | 25 | 34.58 | 864.50 |
| | Total | 50 | | |
| Hasil_IR | BPH | 25 | 14.14 | 353.50 |
| | PIN | 25 | 36.86 | 921.50 |
| | Total | 50 | | |

**Test Statistics[a]**

| | Usia | Proporsi | Hasil_IR |
|---|---|---|---|
| Mann-Whitney U | 312.500 | 85.500 | 28.500 |
| Wilcoxon W | 637.500 | 410.500 | 353.500 |
| Z | .000 | -4.455 | -5.621 |
| Asymp. Sig. (2-tailed) | 1.000 | .000 | .000 |

a. Grouping Variable: Kelompok

```
DATASET ACTIVATE DataSet42.
NPAR TESTS
  /M-W= Usia Proporsi Hasil_IR BY Kelompok(1 3)
  /MISSING ANALYSIS.
```